New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer

References

• Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31(31):3987–3996.
   PubMed Web of Science ®Google Scholar
• Liu Y, Ren Z, Wang J, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is especially beneficial to patients with exon 19 deletion compared with exon 21 L858R mutation in non-small-cell lung cancer: systematic review and meta analysis. Thorac Cancer. 2016;7(4):406–414.
   PubMedGoogle Scholar
• Stewart EL, Tan SZ Liu G, et al. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res. 2015;4(1):67–81.
   PubMed Web of Science ®Google Scholar
• Coco S, Truini A, Vanni I, et al. Uncommon EGFR exon 19 mutations confer gefitinib resistance in advanced lung adenocarcinoma. J Thorac Oncol. 2015;10(6):e50–e52.
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179–1186.
   PubMed Web of Science ®Google Scholar
• Wang S, Tsui ST, Liu C, et al. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer. J Hematol Oncol. 2016;9(1):59.
   PubMed Web of Science ®Google Scholar
• Turke AB, Zejnullahu K, Wu YL, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell. 2010;17(1):77–88.
   PubMed Web of Science ®Google Scholar
• Takezawa K, Pirazzoli V, Arcila ME, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov. 2012;2(10):922–933.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Sequist LV, Arcila ME, et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA. 2012 Jul 31;109(31):E2127–2133.
   PubMed Web of Science ®Google Scholar
• Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390–401.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
   PubMed Web of Science ®Google Scholar
• Coco S, Truini A, Alama A, et al. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition. Target Oncol. 2015 Sep;10(3):393–404.
   PubMed Web of Science ®Google Scholar
• Byers LA, Diao L, Wang J, et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013;19(1):279–290.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012;44(8):852–860.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Du Y, Liu H, et al. Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: a single center, single arm, phase II clinical trial. Thorac Cancer. 2016 Aug 24. DOI:10.1111/1759-7714.12384
   Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–1244.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Aug 26]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000582/WC500029260.pdf
   Google Scholar
• Stahel RA, Dafni U, Gautschi O, et al. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Eur J Cancer. 2015;51(S3):S711–12 (suppl; abstr 3BA).
   Google Scholar
• An C, Zhang J, Chu H, et al. Study of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring EGFR mutation. Pathol Oncol Res. 2016 Oct;22(4):763–768.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Aug 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02319577
   Google Scholar
• Dal Bello MG, Alama A, Barletta G, et al. Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors. Int J Cancer. 2015 Dec 15;137(12):2947–2958.
   PubMed Web of Science ®Google Scholar
• Genova C, Rijavec E, Barletta G, et al. Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15(6):889–903.
   PubMed Web of Science ®Google Scholar
• Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28(2):357–360.
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May;13(5):528–538.
   PubMed Web of Science ®Google Scholar
• Katakami N, Atagi S, Goto K, et al. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol. 2013 Sep 20;31(27):3335–3341.
   PubMed Web of Science ®Google Scholar
• Schuler M, Yang JC, Park K, et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol. 2016;27(3):417–423.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Smit EF, Groen HJ, et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov. 2014 Sep;4(9):1036–1045.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Aug 26]. Available from: https://clinicaltrials.gov/ct2/show/NCT02438722
   Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Tan E, Zhang L, et al. Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7). Abstract # LBA43 presented at the European Society for Medical Oncology (ESMO) 2016 congress; October 7–11; Copenhagen, Denmark.
   Google Scholar
• Yang JC, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(18):3076–3083.
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Giaccone G, Camidge DR, et al. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib. Cancer. 2014;120(8):1145–1154.
   PubMed Web of Science ®Google Scholar
• Cross DA, Ashton SE, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014;4(9):1046–1061.
   PubMed Web of Science ®Google Scholar
• Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009 Dec 24;462(7276):1070–1074.
   PubMed Web of Science ®Google Scholar
• Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372(18):1689–1699.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Tsai C, Shepherd F, et al. AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study. Presented at the 16th World Conference on lung cancer; 2015 Sep 6–9; Denver, CO. (Abstract#1406).
   Google Scholar
• Yang J, Ramalingam SS, Jänne PA, et al. Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol. 2016;11(4 Suppl):S152–S153.
   Web of Science ®Google Scholar
• Zheng D, Ye X, Zhang MZ, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016;6:20913.
   PubMed Web of Science ®Google Scholar
• Sueoka-Aragane N, Katakami N, Satouchi M, et al. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study. Cancer Sci. 2016;107(2):162–167.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Aug 6]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208065s000lbl.pdf
   Google Scholar
• [cited 2016 Aug 6]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004124/WC500202022.pdf
   Google Scholar
• [cited 2016 Aug 6]. Available from: https://clinicaltrials.gov/ct2/show/NCT02151981
   Google Scholar
• Ramalingam SS, Rukazenkov Y, Thomas K, et al. A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. J Clin Oncol. 2015;33 (suppl; abstr TPS8102). Available from: http://meetinglibrary.asco.org/.
   Web of Science ®Google Scholar
• Park K, Lee JS, Han JY, et al. 1300: efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose. J Thorac Oncol. 2016;11(4 Suppl):S113.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Aug 6]. Avaialble from: https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-launches-ambitious-eluxa-trial-programme
   Google Scholar
• [cited 2016 Oct 23]. Available from: https://www.boehringer-ingelheim.com/press-release/boehringer-ingelheim-returns-development-commercial-rights-olmutinib-hanmi
   Google Scholar
• Simmons AD, Jaw-Tsai S, Haringsma HJ, et al. Abstract 793: insulin-like growth factor 1 (IGF1R)/insulin receptor (INSR) inhibitory activity of rociletinib (CO-1686) and its metabolites in nonclinical models. 2015 AACR annual meeting; April 18-22, 2015. Philadelphia, USA; 2015: abstr 793.
   Google Scholar
• Sequist LV, Soria JC, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015;372(18):1700–1709.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Soria JC, Camidge DR. Update to rociletinib data with the RECIST confirmed response rate. N Engl J Med. 2016 Jun 9;374(23):2296–2297.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Aug 6]. Available from: http://www.businesswire.com/news/home/20151116005513/en/
   Google Scholar
• [cited 2016 Aug 6]. Available from: http://www.reuters.com/article/us-clovis-oncology-fda-idUSKCN0X920A
   Google Scholar
• [cited 2016 Aug 6]. Available from: http://global.onclive.com/web-exclusives/clovis-ends-development-of-rociletinib-in-lung-cancer
   Google Scholar
• Yu HA, Spira AI, Horn L, et al. Antitumor activity of ASP8273 300 mg in subjects with EGFR mutation-positive non-small cell lung cancer: interim results from an ongoing phase 1 study. J Clin Oncol. 2016;34 (suppl; abstr 9050). Available from: http://meetinglibrary.asco.org/.
   Web of Science ®Google Scholar
• Goto Y, Nokihara H, Murakami H, et al. ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: preliminary results of first-in-human phase I study in Japan. J Clin Oncol. 2015;33 (suppl; abstr 8014). Available from: http://meetinglibrary.asco.org/.
   Web of Science ®Google Scholar
• Jia Y, Yun CH, Park E, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534(7605):129–132.
   PubMed Web of Science ®Google Scholar
• Reckamp KL, Frankel PH, Mack PC, et al. Phase II trial of XL184 (cabozantinib) plus erlotinib in patients (pts) with advanced EGFR-mutant non-small cell lung cancer (NSCLC) with progressive disease (PD) on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy: a California cancer consortium phase II trial (NCI 9303). J Clin Oncol. 2014;32:5s (suppl; abstr 8014).
   PubMed Web of Science ®Google Scholar
• Neal JW, Dahlberg SE, Wakelee HA, et al. Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): a randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group (E1512). J Clin Oncol. 2015;33 (suppl; abstr 8003). Available from: http://meetinglibrary.asco.org/.
   Google Scholar
• Wu YL, Kim DW, Felip E, et al. Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34 (suppl; abstr 9020). Available from: http://meetinglibrary.asco.org/.
   Web of Science ®Google Scholar
• Scagliotti G, Von Pawel J, Novello S, et al. Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(24):2667–2674.
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Azuma K, Yamamoto N, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-MET inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB(IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Ann Oncol. 2015;26(10):2066–2072.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Ignatius Ou SH, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer. J Clin Oncol. 2014;32:5s (suppl; abstr 8001).
   PubMed Web of Science ®Google Scholar
• [cited 2016 Aug 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT00585195
   Google Scholar
• Li AN, Yang JJ, Zhang XC, et al. Crizotinib in advanced non-small-cell lung cancer with de novo c-Met overexpression. J Clin Oncol. 2015;33:15s (suppl; abstr 8090).
   Google Scholar
• Jänne PA, Shaw AT, Camidge DR, et al. Combined pan-HER and ALK/ROS1/MET inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer: results of a phase I study. J Thorac Oncol. 2016;11(5):737–747.
   PubMed Web of Science ®Google Scholar
• Lara PN Jr, Longmate J, Mack PC, et al. Phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer who previously progressed on erlotinib. Clin Cancer Res. 2015;21(19):4321–4326.
   PubMed Web of Science ®Google Scholar
• Vansteenkinste JF, Canon JL, Braud FD, et al. Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study. J Thorac Oncol. 2015;10(9):1319–1327.
   PubMed Web of Science ®Google Scholar
• Adjei AA, Bennouna J, Leighl NB, et al. Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): results from the phase Ib/II BASALT-2 and BASALT-3 studies. J Clin Oncol. 2016;34 (suppl; abstr e20522). Available from: http://meetinglibrary.asco.org/.
   Google Scholar
• Moran T, Palmero R, Provencio M, et al. A phase Ib open label clinical trial of continuous once daily oral afatinib (A) plus sirolimus (S) in patients (pts) with EGFR mutation positive (EGFR M+) NSCLC and/or disease progression following prior erlotinib (E) or gefitinib (G). Ann Oncol. 2014;25(suppl 4):iv437.
   Google Scholar
• Myers SH, Brunton VG, Unciti-Broceta A. AXL Inhibitors in Cancer: a medicinal chemistry perspective. J Med Chem. 2016;59(8):3593–3608.
   PubMed Web of Science ®Google Scholar
• [cited 2016 Oct 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02424617?term=bgb324&rank=4
   Google Scholar
• [cited 2016 Oct 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02922777?term=bgb324&rank=3
   Google Scholar
• Camidge DR, Doebele RC. Treating ALK-positive lung cancer–early successes and future challenges. Nat Rev Clin Oncol. 2012;9(5):268–277.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Seto T. Updated Evidence on the Mechanisms of Resistance to ALK Inhibitors and Strategies to Overcome Such Resistance: clinical and preclinical data. Oncol Res Treat. 2015;38(6):291–298.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18(5):1472–1482.
   PubMed Web of Science ®Google Scholar
• Boland JM, Jang JS, Li J, et al. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases. J Thorac Oncol. 2013;8(5):574–581.
   PubMed Web of Science ®Google Scholar
• Mengoli MC, Barbieri F, Bertolini F, et al. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: report of two cases and review of the literature. Lung Cancer. 2016; 93:55–58
   Google Scholar
• Facchinetti F, Tiseo M, Di Maio M, et al. Tackling ALK in non-small cell lung cancer: the role of novel inhibitors. Transl Lung Cancer Res. 2016;5(3):301–321.
   PubMed Web of Science ®Google Scholar
• Kort A, Sparidans RW, Wagenaar E, et al. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacol Res. 2015;102:200–207.
   PubMed Web of Science ®Google Scholar
• Isozaki H, Ichihara E, Takigawa N, et al. Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. Cancer Res. 2016;76(6):1506–1516.
   PubMed Web of Science ®Google Scholar
• Tani T, Yasuda H, Hamamoto J, et al. Activation of EGFR bypass signaling by TGFα overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells. Mol Cancer Ther. 2016;15(1):162–171.
   PubMed Web of Science ®Google Scholar
• Fujita S, Masago K, Katakami N, et al. Transformation to SCLC after treatment with the ALK inhibitor alectinib. J Thorac Oncol. 2016;11(6):e67–e72.
   PubMed Web of Science ®Google Scholar
• Dong X, Fernandez-Salas E, Li E, et al. Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small cell lung cancer cells. Neoplasia. 2016;18(3):162–171.
   PubMed Web of Science ®Google Scholar
• Wilson FH, Johannessen CM, Piccioni F, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 2015;27(3):397–408.
   PubMed Web of Science ®Google Scholar
• Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013;56(14):5675–5690.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452–463.
   PubMed Web of Science ®Google Scholar
• Crinò L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866–2873.
   PubMed Web of Science ®Google Scholar
• Felip E, Orlov S, Park K, et al. ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33 (suppl; abstr 8060). Available from: http://meetinglibrary.asco.org/.
   Web of Science ®Google Scholar
• [cited 2016 Aug 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01828099
   Google Scholar
• [cited 2016 Aug 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01828112
   Google Scholar
• Tan DS, Araújo A, Zhang J, et al. Comparative efficacy of ceritinib and crizotinib as initial ALK-targeted therapies in previously treated advanced or metastatic NSCLC: an adjusted comparison with external controls. J Thorac Oncol. 2016 Jun 8. DOI: 10.1016/j.jtho.2016.05.029. [Epub ahead of print].
   Web of Science ®Google Scholar
• [cited 2016 Aug 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf
   Google Scholar
• Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol. 2013;14(7):590–598.
   PubMed Web of Science ®Google Scholar
• Tamura T, Seto T, Nakagawa K, et al. Updated data of a phase 1/2 study (AF-001JP) of alectinib, a CNS-penetrant, highly selective ALK inhibitor in ALK-rearranged advanced NSCLC. Int J Radiat Oncol Biol Phys. 2014;90(5S):S6.
   Google Scholar
• Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol. 2014;15(10):1119–1128.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17(2):234–242.
   PubMed Web of Science ®Google Scholar
• Nokihara H, Hida T, Kondo M, et al. Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): primary results from the J-ALEX study. J Clin Oncol. 2016;34 (suppl; abstr 9008). Available from: http://meetinglibrary.asco.org/.
   Google Scholar
• [cited 2016 Aug 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdf
   Google Scholar
• Rivera VM, Wang F, Anjum R, et al. AP26113 is a dual ALK/EGFR inhibitor: characterization against EGFR T790M in cell and mouse models of NSCLC. Cancer Res. 2012;72 (abstr 1794). Available from: http://cancerres.aacrjournals.org/content/72/8_Supplement/1794.
   Web of Science ®Google Scholar
• Rosell R, Gettinger SN, Bazhenova LA, et al. 1330: brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial. J Thorac Oncol. 2016;11(4 Suppl):S114.
   Google Scholar
• [cited 2016 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02094573
   Google Scholar
• [cited 2016 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02737501
   Google Scholar
• [cited 2016 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02706626
   Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h[2,5,11-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720–4744.
   PubMed Web of Science ®Google Scholar
• Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374(1):54–61.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Bauer TM, Felip E, et al. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS1+ non-small cell lung cancer (NSCLC). J Clin Oncol. 2016;34 (suppl; abstr 9009). Available from: http://meetinglibrary.asco.org/.
   Web of Science ®Google Scholar
• [cited 2016 Aug 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02097810
   Google Scholar
• Drilon A, De Braud FG, Siena S, et al. Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements. 2016 AACR Annual Meeting; New Orleans, USA; 2016: abstr 2136. Available from: http://cancerres.aacrjournals.org/content/76/14_Supplement/CT007.
   Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 Jun;4(6):662–673.
   PubMed Web of Science ®Google Scholar
• McKeage K. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer. Drugs. 2015;75(1):75–82.
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Zhang S, Graeme Hodgson J, et al. Activity of brigatinib (BRG) in crizotinib (CRZ) resistant patients (pts) according to ALK mutation status. J Clin Oncol. 2016;34 (suppl; abstr 9060). Available from: http://meetinglibrary.asco.org/.
   Web of Science ®Google Scholar
• Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346(6216):1480–1486.
   PubMed Web of Science ®Google Scholar
• Hrustanovic G, Olivas V, Pazarentzos E, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med. 2015;21(9):1038–1047.
   PubMed Web of Science ®Google Scholar
• Kawamura T, Kenmotsu H, Taira T, et al. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure. Cancer Sci. 2016;107(7):1001–1005.
   PubMed Web of Science ®Google Scholar
• Ulivi P. Non-invasive methods to monitor mechanisms of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer: where do we stand? Int J Mol Sci. 2016 Jul 22;17(7). pii: E1186.
   PubMed Web of Science ®Google Scholar
• Jin Y, Shao Y, Shi X, et al. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing. Oncotarget. 2016 Aug;12. DOI:10.18632/oncotarget.11237. [Epub ahead of print].
   Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7:11815.
   PubMed Web of Science ®Google Scholar
• Escriu C, Field JK. Circulating tumour DNA and resistance mechanisms during EGFR inhibitor therapy in lung cancer. J Thorac Dis. 2016;8(9):2357–2359. DOI:10.21037/jtd.2016.07.96
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Bhattacharya S, Socinski MA, et al. HSP90 inhibitors in lung cancer: promise still unfulfilled. Clin Adv Hematol Oncol. 2016;14(5):346–356.
   PubMed Web of Science ®Google Scholar